Week of August 6, 2012: Boehringer, Servier, Xoma Form Biomanufacturing Agreement; Teva Canada Completes Sale of Mirabel (Quebec) Facility to Halo Pharmaceutical; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of August 6, 2012: Boehringer, Servier, Xoma Form Biomanufacturing Agreement; Teva Canada Completes Sale of Mirabel (Quebec) Facility to Halo Pharmaceutical; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Boehringer Ingelheim has entered into an agreement with Servier and its partner Xoma to transfer Xoma’s technology and process for the commercial manufacture of gevokizumab, Xoma’s novel interleukin 1-beta (IL-1β) allosteric modulating antibody for treating noninfectious uveitis. Upon completion of the transfer and the establishment of biological comparability, Boehringer Ingelheim is expected to produce gevokizumab at its facility in Biberach, Germany, for Servier’s commercial use. Additionally, Servier and Xoma will retain all rights to the development and commercialization of gevokizumab. Read More

Gilead Sciences, Mylan Laboratories, and the Indian pharmaceutical companies Ranbaxy Laboratories and Strides Arcolab, have agreed to collaborate on promoting access to generic versions of Gilead’s HIV medicine emtricitabine (FTC) in developing countries—including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine coformulated with other Gilead HIV medicines. Under the new agreements, Gilead will provide a technology transfer for the manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce overall manufacturing costs. Read More

Teva Canada has completed the sale of Teva’s Mirabel (Montreal, Quebec) manufacturing facility to the CDMO Halo Pharmaceutical on July, 31, 2012. Under the terms of the sale, Teva Canada and Halo have established manufacturing agreements. Halo will continue to manufacture all products currently produced at the Mirabel site until the end of 2012. Afterwards, manufacturing operations will be transferred to Teva’s Stouffville, Ontario, facility. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here